KPTI's price/sales ratio is 12.39; that's higher than the P/S ratio of 85.62% of US stocks.
As for revenue growth, note that KPTI's revenue has grown 295.95% over the past 12 months; that beats the revenue growth of 97.7% of US companies in our set.
Karyopharm Therapeutics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -18%, greater than the shareholder yield of only 14.31% of stocks in our set.
Stocks that are quantitatively similar to KPTI, based on their financial statements, market capitalization, and price volatility, are FBIO, PROF, QUIK, ATNX, and RDUS.
Karyopharm Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company was founded in 2008 and is based in in Newton, Massachusetts.
Karyopharm Therapeutics ([[KPTI]] -8.0%) expects total Q4 revenues to be between $35M-36M and between $108M-109M for the FY of 2020, including net product sales for XPOVIO.Additionally, company expects net product sales of XPOVIO to be between $20M-20.5M during Q4 and between $76M- -76.5M for the FY 2020.Net sales for Q4 were...
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2020 total revenue estimates including net product sales for XPOVIO, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, and provided additional updates on XPOVIO's commercial progress.
Antengene has submitted an Investigational New Drug ((IND)) application for ATG-010 (selinexor, XPOVIO) being co-developed by Karyopharm Therapeutics (KPTI) to the National Medical Products Administration ((NMPA)) in the treatment of Endometrial Cancer.The Phase 3, double-blind trial ((SIENDO)) aims to evaluate the efficacy of ATG-010 compared to placebo as maintenance therapy in patients with advanced...
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Monday, January 11 at 4:30 p.m. ET, followed by a question and answer breakout session at 4:50 p.m. ET.